Key result
Plasma dopamine-beta-hydroxylase activity did not differ significantly between hypertensive patients and normotensive controls.
Why the study?
Does plasma dopamine-β-hydroxylase activity differ between hypertensive patients and normotensive controls?
Case-Control (n=146)
Does plasma dopamine-β-hydroxylase activity differ between hypertensive patients and normotensive controls?
Plasma dopamine-β-hydroxylase activity does not appear to be significantly altered in hypertensive patients compared to controls, nor does it correlate with resting blood pressure.
Answers are grounded in this paper and cite their sources.
Plasma DBH lacks diagnostic value in hypertension; leaves open its pathophysiological role.
Dopamine‐β‐hydroxylase (DBH), the enzyme responsible for the biosynthesis of noradrenaline from dopamine, has been assayed in the blood plasma of S3 hypertensive patients. The results were compared with those from a control group of 93 adults. The plasma DBH activity varied within a wide range in both hypertensives and controls. There was no difference between the average DBH activity nor any significant relation between the resting recumbent systolic or diastolic BP and the plasma DBH activity. In a subsample of the material, consisting of 11 patients and controls matched for age and sex, the DBH activity was studied at 3‐hour intervals during 12 hours in an attempt to estimate the variation of each individual. No significant difference was found between the two groups.
No takes yet. Share an insight, caveat, or question.
Åberg et al. (1974) conducted a case-control in Hypertension (n=146). Hypertension vs. Normotensive controls was evaluated on Plasma dopamine-beta-hydroxylase (DBH) activity. Plasma dopamine-beta-hydroxylase activity did not differ significantly between hypertensive patients and normotensive controls.
Synapse has enriched 10 related papers. Consider them for comparative context: